Felip E, Moreno V, Morgensztern D, Curigliano G, et al. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol 2022;89:499-514.
PMID: 35298698